louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06191705: Urdu Translation, Validity and Reliability of Quick Disabilities of Arm, Shoulder & Hand (QuickDASH)
Official title: Urdu Translation, Validity and Reliability of Quick Disabilities of Arm, Shoulder & Hand (QuickDASH)
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Shoulder Pain
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-01-05
Enrollment: 50
Sex: ALL
Minimum age (years): 19
Maximum age (years): 44
Standard ages: ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with for shoulder, arm/wrist, or hand musculoskeletal injury/pain/symptoms.

Brief summary: The purpose of this study is to translate Quick Disabilities of Arm, Shoulder \& Hand (QuickDASH) into Urdu and determine the validity and reliability of the Urdu version of QuickDASH.


Eligibility criteria: Inclusion Criteria:

Individuals with for shoulder, arm/wrist, or hand musculoskeletal injury/pain/symptoms. Capable of understanding and completing the self-reported questionnaires. The exclusion criteria were the -

Exclusion Criteria:

Presence of any systemic disease or any neurological disorder. The upper limb involvement is due to any recent surgery in less than 6 weeks.

-

Primary outcomes:
measure: QuickDASH
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University Islamabad
Study officials:
References:
Clinical trial NCT00899405: Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
Official title: EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer
Keywords: lung cancer
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2009-05-12
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with lung cancer

Brief summary: RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Detailed description: OBJECTIVES:

* Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
* Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.

OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* May have received prior EGFR inhibitors

Primary outcomes:
measure: Mutational status of the EGFR pathway
timeFrame: up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Cancer Center
state: California
Study officials:
affiliation: University of California, Davis
name: Philip C. Mack, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00840905: A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Official title: A Pilot Observational Study to Determine the Prevalence of HPV Serology in HIV Seropositive Women From Subsaharan Africa and Brasil
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV
HIV Infections
Keywords: HPV
Lead sponsor: University of Witwatersrand, South Africa
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2009-02-11
Enrollment: 487
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HIV seropositive women from South Africa, Botswana, and Brasil

Brief summary: This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer. Different types are more likely to lead to cancer than other types. A vaccine has been made to fight infection against HPV 16 and 18 which has been shown to cause cervical cancer in America and Europe. What HPV type cause cancer in other countries is not as well studied.

Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be \<50% in HIV seropositive women in resource limited countries.

Detailed description: Plasma from HIV seropositive women will be taken and sent to MERCK in the USA to evaluate what the antibody titers of HPV 6,11,16 and 18. .

Eligibility criteria: Inclusion Criteria:

* HIV seropositive women 18 years of age and older Consent signed per local IRB requirement

Exclusion Criteria:

* Can not give blood

Primary outcomes:
measure: To determine the seroprevalence of HPV types 6,11,16,18 in HIV serOpositive women for Botswana, South Africa and Brazil
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Habarone
country: Botswana
facility: Shahin Lockman
city: Rio De Janeiro
country: Brazil
facility: Fundacao Oswaldo Cruz
city: Johannesburg
country: South Africa
facility: University of Witwatersrand/Helen Joseph Hospital
Study officials:
affiliation: Clinical HIV Research Unit University of Witwatersrand
name: Cynthia S Firnhaber, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03296605: Development of Obesity and Bariatric Surgery
Official title: Impacts of Bariatric Surgery on Obesity in China
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Obesity
Keywords: Obesity
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor class: OTHER
First posted: 2017-09-28
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obesity patients and controls

Brief summary: This study focus on the cause of obesity and impacts of bariatric surgery on it.


Eligibility criteria: Inclusion Criteria:

1. Body mass index ≥18 kg/m2
2. already received bariatric surgery or abdonimal surgery

Exclusion Criteria:

1. acute stroke or acute myocardial infarction in 6 months
2. autoimmune disease
3. long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs
4. pregnancy
5. consists with other endocrine diseases
6. acute infection in2 weeks
7. cancer
8. use of antibiotics in 3 months
9. chronic digestive inflammations 9

Primary outcomes:
measure: Immunity cells
timeFrame: up to 5 years
Secondary outcomes:
measure: Body weight and height
timeFrame: up to 5 years
measure: Insulin
timeFrame: up to 5 years
measure: Cytokine
timeFrame: up to 5 years
measure: Cognitive Assessment (MMSE)
timeFrame: up to five years
measure: Cognitive Assessment (MoCA)
timeFrame: up to 5 years
measure: Cognitive Assessment (RBANS)
timeFrame: up to 5 years
measure: Cognitive Assessment (processing speed)
timeFrame: up to 5 years
measure: Cognitive Assessment (executive function)
timeFrame: up to 5 years
measure: brain structure and activation in fMRI
timeFrame: up to 5 years
Other outcomes:
Locations:
city: Nanjing
country: China
facility: at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
state: Jiangsu
Study officials:
References:
citation: Liu F, He J, Liu B, Zhang P, Wang H, Sun X, Chu X, Guan W, Feng W, Bi Y, Zhu D. Association of Omental Adipocyte Hypertrophy and Fibrosis with Human Obesity and Type 2 Diabetes. Obesity (Silver Spring). 2021 Jun;29(6):976-984. doi: 10.1002/oby.23155. Epub 2021 May 4.
citation: Yuan X, Chen J, Cheng Q, Zhao Y, Zhang P, Shao X, Bi Y, Shi X, Ding Y, Sun X, Xue B. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery. BMC Gastroenterol. 2018 Oct 3;18(1):147. doi: 10.1186/s12876-018-0871-2.
citation: Zhang P, Ge Z, Wang H, Feng W, Sun X, Chu X, Jiang C, Wang Y, Zhu D, Bi Y. Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol. 2018 Jun;68(6):1247-1255. doi: 10.1016/j.jhep.2018.01.035. Epub 2018 Feb 13.
Clinical trial NCT02523105: Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment
Official title: Evaluation of Use of Brain Activity Monitoring for Early Identification of Pharmaceutical Treatment Efficacy and Development of Depression Deterioration Events.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Lead sponsor: Brainmarc Ltd.
Sponsor class: INDUSTRY
First posted: 2015-08-14
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study evaluates the use of brain activity monitoring for early identification of pharmaceutical treatment efficacy and development of depression deterioration events.

Detailed description: The study will be conducted in two arms:

In arm I, participants diagnosed with depression. In arm II, healthy participants.

Arm I - Participants that need to start or switch their pharmacological antidepressant therapy will be recruited. Their clinical status will be evaluated and their EEG characteristics will be collected.

Arm II - Clinical and EEG characteristics of Healthy volunteers will collected on a similar timetable.

Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged 18 -70 years (Adult, Senior)
* Able and willing to comply with all study requirements.

Additional Inclusion Criteria for Arm I

* Diagnosed with depression
* Being within 2 days of receiving pharmaceutical treatment for depression for the first

time or changing dose or changing type of current pharmaceutical treatment or addition to

drug of current pharmaceutical treatment.

Additional Inclusion Criteria for Arm II

Brief Symptom Inventory (BSI \< 2.3).

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

* Diagnosed with Psychotic disorder.
* Diagnosed with Central Neurological disorder.
* A user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse

or dependence.

* Hearing disorder and/or known ear drum impairment.
* High suicide risk as judged by the research team.

Primary outcomes:
measure: Tuning and evaluation of use of EEG analysis of brain prefrontal activity for mental status evaluation.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: 'Afula
country: Israel
facility: Haemek medical center
city: Hod Hasharon
country: Israel
facility: Shalvata Hospital
Study officials:
affiliation: Shalvata Hospital
name: Yuval Bloch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02043405: Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity
Official title: Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Pre-diabetes
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: American Diabetes Association
First posted: 2014-01-23
Enrollment: 21
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators will use exercise training and weight loss to discover localized lipid species related to diabetes risk in people.


Eligibility criteria: Inclusion Criteria:

* Obese men and women with pre-diabetes; (BMI 30-40 kg/m2)
* Ages ranging from 30-60 years old;
* Individuals with:

  * impaired fasting glucose (IFG), (between 100-125mg/dl, with post-prandial glucose (\<140 mg/dl 2 hrs after 75g OGTT)
  * impaired glucose tolerance (IGT), (normal fasting glucose \<100mg/dl, with post-prandial glucose (\>140 mg/dl 2 hrs after 75g OGTT)
  * a combination of the two (IFG/IGT) (both impaired fasting glucose (100-125mg/dl), and impaired glucose tolerance (\>140 mg/dl 2 hrs after 75g OGTT), will be verified using oral glucose tolerance testing at initial screening, and
* Sedentary (\<2 hours/week of planned physical activity).

To increase generalizability, and because each subject serves as their own control, women will be enrolled regardless of menopausal status, use of hormone replacement therapy and oral contraceptives.

Exclusion Criteria:

* Regular exercise more than 2 hours/week,
* medications that could affect glucose,
* lipid metabolism,
* thyroid disease,
* history of lung disease,
* pregnancy,
* active cigarette smoking or exposure to second hand smoke, and
* Severe plasma lipid disorders.

Primary outcomes:
measure: Change in insulin sensitivity
timeFrame: baseline and 3 months
Secondary outcomes:
measure: Change in membrane localized diacylglycerol species
timeFrame: baseline and 3 months
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Bryan Bergman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02605005: The Impact of a Beach Chair Position During Shoulder Arthroscopy on Regional Cerebral Oxygen Saturation : Comparison of Interscalene Block and General Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Impaired Oxygen Delivery
Cerebral Hypoxia
Keywords: interscalene block, general anesthesia, shoulder arthroscopy, cerebral oxygen saturation, beach chair position
Lead sponsor: Osijek University Hospital
Sponsor class: OTHER
First posted: 2015-11-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients for elective arthroscopy of the shoulder

Brief summary: The aim of this study is to investigate the relationship between the patient positioning in the beach chair position with consequential arterial pressure changes and their influence on regional cerebral oxygen saturation under two anesthesia techniques, general anesthesia in one group of patients and interscalene block in the second group of patients.

Detailed description: The participants of the study are patients scheduled for elective shoulder athroscopy. The patients randomise themselves by choosing the type of anesthesia technique (general anesthesia or interscalene block) after detailed description of both techniques. They receive the standard, routine medical care (monitoring and anesthesia techniques) during which the obtained data of arterial pressure, heart rate, peripheral and cerebral oxygen saturation will be statistically analysed and compared.

Eligibility criteria: Inclusion Criteria:

Inclusion criterion for the study was the approval for surgery under general or regional anesthesia with ASA I and ASA II patients classification. -

Exclusion Criteria:

* The patients who have refused to take part in the study, patients assessed as ASA III or higher, who have cerebrovascular or coronary disease, coagulopathy, hypersensitivity to local anesthetics or other contraindications to one or the other type of anesthetic techniques All patients in whom the operation lasted less than 20 minutes or longer than 90 minutes, have been also excluded from the study.

Primary outcomes:
measure: changes in arterial pressure from baseline
timeFrame: baseline, during the operation, one hour after the operation
Secondary outcomes:
measure: changes in regional cerebral oxygen saturation from baseline
timeFrame: baseline, during the operation, one hour after the operation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00501605: Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Official title: A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumor
Liver Metastases
Keywords: Phase I
AZD2171
advanced solid tumors
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-07-16
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.


Eligibility criteria: Inclusion Criteria:

* Provision of written informed consent
* Male/female, 18 yr or over
* WHO status 0-2
* Refractory advanced solid tumor

Exclusion Criteria:

* Radiotherapy within 4 weeks of starting AZD2171 treatment
* Low haemoglobin level
* Low platelet or neutrophil counts

Primary outcomes:
measure: primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.
Secondary outcomes:
measure: PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression
Other outcomes:
Locations:
city: Freiburg
country: Germany
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: Nick Botwood, BSc, MBBS, MRCP, MFPM
role: STUDY_DIRECTOR
affiliation: Klinik fur.Internistische Onkologie
name: J. Drevs, PD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04670705: Relationship of CP and AP
Official title: The Prevalence of Acute Pancreatitis Episodes Among Patients With Chronic Pancreatitis and the Associated Factors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Pancreatitis
Acute Pancreatitis
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
First posted: 2020-12-17
Enrollment: 1022
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consequent patients with a diagnosis of CP were enrolled between January 2010 to December 2015 after informed consents obtained.The diagnosis of CP was established based on the findings of computed tomography, magnetic resonance imaging, or endoscopic ultrasound, in accordance with the Asia-Pacific consensus.

Brief summary: The present study aimed to determine the prevalence of AP attacks before the diagnosis of CP and further identified the potential associated factors for AP episodes.


Eligibility criteria: Inclusion Criteria:

* Consequent patients with a diagnosis of CP between January 2010 to December 2015
* informed consents provided

Exclusion Criteria:

* autoimmune pancreatitis (AIP)
* pancreatic cancer diagnosed within 2 years after the diagnosis of CP

Primary outcomes:
measure: the occurrence of acute pancreatitis
timeFrame: Baseline (before the diagnosis of CP)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00000205: Buprenorphine Maintenance Protocol - 1
Official title: Buprenorphine Maintenance Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Opioid-Related Disorders
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of buprenorphine versus methadone.


Eligibility criteria: Inclusion Criteria:

M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and /or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe

Primary outcomes:
measure: Retention
measure: Opiate use
measure: Opiate craving
measure: Adverse events
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Friends Research Institute
state: California
Study officials:
affiliation: Friends Research Institute, Inc.
name: Walter Ling, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996 May;53(5):401-7. doi: 10.1001/archpsyc.1996.01830050035005.
citation: Compton PA, Ling W, Charuvastra VC, Wesson DR. Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. J Addict Dis. 1995;14(3):97-114. doi: 10.1300/J069v14n03_07.
citation: Compton PA, Ling W, Wesson DR, Charuvastra VC, Wilkins J. Urine toxicology as an outcome measure in drug abuse clinical trials: must every sample be analyzed? J Addict Dis. 1996;15(2):85-92. doi: 10.1300/J069v15n02_07.
Clinical trial NCT01212705: Effect of Adaptive Servoventilation on Cardiac Function in Chronic Heart Failure and Cheyne-Stokes Respiration
Official title: Effect of Adaptive Servoventilation on Cardiac Function, Exercise Tolerance and Quality of Life in Patients With Chronic Heart Failure and Cheyne-Stokes Respiration
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Heart Failure
Central Sleep Apnea
Cheyne-Stokes Respiration
Lead sponsor: Military Institute od Medicine National Research Institute
Sponsor class: OTHER
First posted: 2010-10-01
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT

Brief summary: Sleep disordered breathing is common in patients with chronic heart failure. Adaptive servoventilation is a novel method of treatment central sleep apnoea, especially associated with Cheyne-Stokes-respiration. The aim of the study is to investigate effect of adaptive servoventilation on cardiac function, exercise tolerance and quality of life in patients with chronic heart failure.


Eligibility criteria: Inclusion Criteria:

* chronic heart failure with ejection fraction ≤45%
* optimal medical treatment for at least 1 month
* clinical diagnosis of Cheyne-Stokes respiration

Exclusion Criteria:

* unstable heart failure
* stroke
* transient ischemic attack in last 6 months
* pacemaker, cardioverter-defibrillator or resynchronization device implanted less than 6 months before study entrance
* severe chronic obstructive pulmonary disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Military Institute of Medicine
state: Szaserow 128
Study officials:
affiliation: Military Institute of Medicine
name: Anna Kazimierczak
role: PRINCIPAL_INVESTIGATOR
References: